Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.

GJ, Criner; FM, Lang; RL, Gottlieb; KS, Mathews; TS, Wang; TW, Rice; D, Madduri; S, Bellam; R, Jeanfreau; AH, Case; MK, Glassberg; GM, Lyon; K, Ahmad; R, Mendelson; JM, DiMaio; MP, Tran; CW, Spak; JA, Abbasi; SG, Davis; S, Ghamande; S, Shen; L, Sherman; S, Lowry

doi:10.1164/rccm.202108-1859oc

Public

Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.

Shared by NobleBlocks on Jun 1, 2022 • 12:00 AM UTC

Authors:

Criner GJ

Lang FM

Gottlieb RL

Abstract

Rationale: GM-CSF (granulocyte-macrophage colony-stimulating factor) has emerged as a promising target against the hyperactive host immune response associated with coronavirus disease (COVID-19). Objectives: We sought to investigate the efficacy and safety of gimsilumab, an anti-GM-CSF monoclonal an...

Subject

GM-CSF

Acute respiratory distress syndrome

Covid-19

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!